TEVA Teva- Pharmaceutical Industries Ltd. - ADR

$TEVA reported earnings this morning before the open and beat EPS estimates: $0.86 adjusted EPS vs $0.72 expected, according to Stock Meadow.

$TEVA Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.86 up 10.26% YoY • Reported revenue of $4.39B down -1.90% YoY • Teva raised 2026 revenue guidance to $16.7B and non-GAAP diluted EPS guidance to $1.92; free cash flow guidance is $2.1B, with higher outlooks for AUSTEDO, AJOVY and UZEDY.

$TEVA The streets of TEVA have been pretty quiet since the roosters stopped crowing and the loud and rusty Porsche stopped speeding down it a few times a day.

$TEVA My Amgen stock hit another 52 week high. See Teva to $45. TEVA is a strong valued stock that continues making its great mark for its product lines and business.

$TEVA $40.24 bid. Holding long positon at profit RETAIN POSITION BRIEF: Teva completed the acquisition of BioXcel Therapeutics (BTAI) neuroscience assets, including worldwide rights to BXCL501 and hospital-use IGALMI. BXCL501 is under FDA review for at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults; Teva said it could be the first approved at-home option if cleared. Deal was completed through a court-supervised Section 363 sale and does not include an acquisition of BioXcel Therapeutics itself. Teva is paying $57.5 mln upfront plus up to $67.5 mln in contingent payments tied to regulatory timing and sales milestones.

$TEVA Sanofi up 5% on today’s news although the lion part of the duvakitug deal is Teva’s

$TEVA FDA approved Weltruza on Friday, the first once-monthly subcutaneous olanzapine for schizophrenia. Teva expects US launch in the coming weeks. Compare it with the only other long-acting olanzapine, Zyprexa Relprevv: that one is intramuscular, needs 3 hours of post-injection observation in a certified facility under a REMS program, and patients can't drive home after. Weltruza drops all of that, no loading doses or oral supplementation either. Second US approval from the MedinCell SteadyTeq platform after Uzedy (risperidone, 2023). Shares hit fresh 52-week highs Friday.

$TEVA — Teva's stock shows upward momentum driven by FDA approval for schizophrenia treatment, alongside mixed financial performance. Recent analyses covered Teva Pharmaceutical Industries Limited (TEVA), noting its stock's upward momentum with positive short-term and long-term trends indicated by moving averages and RSI. The company's financial performance showed a slight year-over-year revenue decrease and a quarterly net loss, contrasting with a full-year net income in 2025. A key catalyst discussed was the FDA approval for a monthly schizophrenia shot, contributing to a year-to-date stock surge. On the upside: Stock trading above 50-day and 200-day SMAs, indicating positive medium and long-term trends. Positive short-term momentum indicated by 7-day, 30-day, and 91-day price changes. Positive MACD indicating bullish momentum. On the risk side: Quarterly revenue showed a year-over-year decrease of 0.8%. Reported a net loss of $576 million for the latest reported quarter.

$TEVA looking good in the neighborhood! Should be a productive next few months, and beyond

$TEVA Teva Pharmaceutical Industries Ltd. (NYSE: TEVA): One of the largest generic manufacturers globally, producing oral formulations across all four classes (ciprofloxacin, levofloxacin, moxifloxacin, doxycycline).

In the black at Teva Pharmaceutical Industries. $706M over the past 12 months, after losing $158M the year before. Scores a 16, top 100 of 3,283 stocks. $TEVA

$TEVA pre market bad because of the worries about TASE. Then the TASE is doing great. Just bullish.

$TEVA: fee math on the QVAR deal. The $35M antitrust fund could lose up to $11.5M to attorneys fees, leaving about $23.5M before admin costs for pro rata payments. Claims closed July 31, payments pending. Open Class Actions.

$TEVA: watch for QVAR settlement scams. Legit claims in the $35M antitrust deal never charge a fee to file or release payment, and the administrator does not need your bank password. Claims closed July 31. Open Class Actions.

$TEVA update: besides the $35M QVAR fund, Teva agreed to pull QVAR patents from the FDA Orange Book, which could help generic inhalers reach market. The suit alleges Teva stalled them. Claims closed; no payout date yet. Open Class Actions.

$TEVA it will be interesting come November 14- with the FDA approval of Igalmi for home use. Should be a huge market for this drug treating adgitation secondary to schizophrenia, Alzheimer’s, PTSD…

$TEVA Q3 revenue of USD 4.4B fell 2%, but the mix matters more than the total. Generics dropped 16% on Revlimid competition, while AUSTEDO, AJOVY and UZEDY together brought in about USD 1.1B, up 33%. Full-year revenue guide moved up to USD 16.7-17.0B from USD 16.5-16.85B.

$TEVA Undervalue of the score 82 and high quality of the product line of score 93 with strong financial quality of score 96. This is a very great long term investment for your retirement.

$TEVA $41.45 +0.75 DAC (dollar average cost includes partials SELLS at a profit to reduce cost to zero). https://stocktwits.com/G101SPM/message/664258337 UPDATE: Teva Pharma beats by $0.14, beats on revs; guides FY26 EPS in-line, revs above consensus note: Reports Q3 (Sep) earnings of $0.86 per share, excluding non-recurring items, $0.14 better than the FactSet Consensus of $0.72; revenues fell 1.9% year/year to $4.39 bln vs the $4.23 bln FactSet Consensus. Co issues guidance for FY26, sees EPS of $1.92-2.11, excluding non-recurring items, vs. $2.03 FactSet Consensus; sees FY26 revs of $16.7-17.0 bln vs. $16.59 bln FactSet Consensus. Adjusted EBITDA: $4.23--$4.43 billion; includes $0.87 billion of acquired IPR&D charges Free cash flow: $2.1--$2.4 billion AUSTEDO revenues: $2.55 billion--$2.65 billion AJOVY revenues: $930 million--$960 million UZEDY revenues: $290 million--$310 million

$TEVA 🤝 Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. entered a license and commercialization agreement for two FDA-approved immunology biosimilars, with Teva obtaining U.S. commercialization rights for ETICOVO upon close and infliximab-abda in Q3 2027.